1
|
Abreu Diaz AM, Rodriguez Riera Z, Lee Y, Esteves LM, Normandeau CO, Fezas B, Hernandez Saiz A, Tournoux F, Juneau D, DaSilva JN. [ 18 F]Fluoropyridine-losartan: A new approach toward human Positron Emission Tomography imaging of Angiotensin II Type 1 receptors. J Labelled Comp Radiopharm 2023; 66:73-85. [PMID: 36656923 DOI: 10.1002/jlcr.4014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 12/27/2022] [Accepted: 01/17/2023] [Indexed: 01/21/2023]
Abstract
Angiotensin II type 1 receptors (AT1 R) blocker losartan is used in patients with renal and cardiovascular diseases. [18 F]fluoropyridine-losartan has shown favorable binding profile for quantitative renal PET imaging of AT1 R with selective binding in rats and pigs, low interference of radiometabolites and appropriate dosimetry for clinical translation. A new approach was developed to produce [18 F]fluoropyridine-losartan in very high molar activity. Automated radiosynthesis was performed in a three-step, two-pot, and two-HPLC-purification procedure within 2 h. Pure [18 F]FPyKYNE was obtained by radiofluorination of NO2 PyKYNE and silica-gel-HPLC purification (40 ± 9%), preventing the formation of nitropyridine-losartan in the second step. Conjugation with trityl-losartan azide via click chemistry, followed by acid hydrolysis, C18-HPLC purification and reformulation provided [18 F]fluoropyridine-losartan in 11 ± 2% (decay-corrected from [18 F]fluoride, EOB). Using tris[(1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl]-amine (THPTA) as a Cu(I)-stabilizing agent for coupling [18 F]FPyKYNE to the unprotected losartan azide afforded [18 F]fluoropyridine-losartan in similar yields (11 ± 3%, decay-corrected from [18 F]fluoride, EOB). Reverse-phase HPLC was optimized by reducing the pH of the mobile phase to achieve complete purification and high molar activities (467 ± 60 GBq/μmol). The use of radioprotectants prevented tracer radiolysis for 10 h (RCP > 99%). The product passed the quality control testing. This reproducible automated radiosynthesis process will allow in vivo PET imaging of AT1 R expression in several diseases.
Collapse
Affiliation(s)
- Aida Mary Abreu Diaz
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- Département de pharmacologie et physiologie, Faculté de médecine, Université de Montréal, Pavillon Paul-G. Desmarais, Montréal, Québec, Canada
- Institut de génie biomédical, Faculté de médecine, Université de Montréal, Pavillon Paul-G. Desmarais, Montréal, Québec, Canada
- Departamento de Radioquímica, Instituto Superior de Tecnologías y Ciencias Aplicadas, Universidad de la Habana, La Habana, Cuba
| | - Zalua Rodriguez Riera
- Departamento de Radioquímica, Instituto Superior de Tecnologías y Ciencias Aplicadas, Universidad de la Habana, La Habana, Cuba
| | - Yanick Lee
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- Institut de génie biomédical, Faculté de médecine, Université de Montréal, Pavillon Paul-G. Desmarais, Montréal, Québec, Canada
| | - Luis Miguel Esteves
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- CRCHUM site, Isologic Innovative Radiopharmaceuticals, Lachine, Québec, Canada
| | | | - Baptiste Fezas
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
| | | | - François Tournoux
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- Centre cardiovasculaire, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
| | - Daniel Juneau
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- Médecine nucléaire, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
- Département de radiologie, radio-oncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Pavillon Roger-Gaudry, Montréal, Québec, Canada
| | - Jean N DaSilva
- Laboratoire de Radiochimie et Cyclotron, Centre de Recherche du CHUM, Montréal, Québec, Canada
- Département de pharmacologie et physiologie, Faculté de médecine, Université de Montréal, Pavillon Paul-G. Desmarais, Montréal, Québec, Canada
- Institut de génie biomédical, Faculté de médecine, Université de Montréal, Pavillon Paul-G. Desmarais, Montréal, Québec, Canada
- Département de radiologie, radio-oncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Pavillon Roger-Gaudry, Montréal, Québec, Canada
| |
Collapse
|